Status:
COMPLETED
Adherence to HU and HRQOL in Patients With Sickle Cell Disease: An Intervention Study Using HU-Go App
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago
Conditions:
Sickle Cell Disease
Sickle B+ Thalassemia
Eligibility:
All Genders
12-25 years
Phase:
NA
Brief Summary
This project addresses three important research questions. First, adolescents and young adults (AYA) with sickle cell disease (SCD) and their parents/caregivers will be engaged to inform the (1) domai...
Detailed Description
Aim 1: Identify the needs, desires, concerns, and expectations of AYA patients with SCD and their parents/caregivers that will guide implementation of a mHealth tool, HU-Go, designed to improve adhere...
Eligibility Criteria
Inclusion
- At least 12 years old at the time of study enrollment
- Diagnosis of sickle cell disease (hemoglobin SS or SC or S/B 0 thalassemia) confirmed by hemoglobin electrophoresis
- On hydroxyurea
- Own or have access to a smartphone
- Be able to speak and read English
Exclusion
- Chronic monthly transfusion support
- Any hemoglobinopathy other than sickle cell disease
Key Trial Info
Start Date :
May 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 11 2020
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT04675645
Start Date
May 15 2018
End Date
July 11 2020
Last Update
July 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611